Esperion Therapeutics Inc/ US29664W1053 /
2024-04-17 10:00:00 PM | Chg. -0.0700 | Volume | Bid1:33:22 AM | Ask1:33:22 AM | High | Low |
---|---|---|---|---|---|---|
1.8400USD | -3.66% | 3.72 mill. Turnover: 6.53 mill. |
1.8200Bid Size: 4,300 | 1.9200Ask Size: 3,300 | 1.9600 | 1.8100 |
GlobeNewswire
04-07
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (...
GlobeNewswire
03-27
One Biosciences Welcomes Dr. Scott Braunstein and Dr. Vincent Miller to its Board of Directors
GlobeNewswire
03-25
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & ...
GlobeNewswire
03-22
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiova...
GlobeNewswire
03-22
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose ...
GlobeNewswire
02-13
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
GlobeNewswire
01-23
Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ ...
GlobeNewswire
01-03
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including...
GlobeNewswire
2023-12-13
U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXL...
GlobeNewswire
2023-11-13
Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at Ame...
GlobeNewswire
2023-11-11
Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American...
GlobeNewswire
2023-08-28
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference